Special Reports

2020 Virtual Med Ad News Manny Awards – “FamilyStyle”

COVID-19 Crisis, Coronavirus Disease (COVID-19) Pandemic, Drugs, Healthcare Communications Agencies, Healthcare Communications Networks, Manny Awards, Marketing & Advertising, Med Ad News, Social media

For many of us, we’re entering week 8 of Work From Home during the Covid-19 crisis. It’s been inspiring to see all those in the healthcare communications universe innovate and remain motivated to continue our critical work during these challenging times. It’s fair to say that now, more than ever, the role of effectively communicating the research, development, administration and efficacy of drug therapies is paramount to successfully navigating the world through this pandemic and beyond. We invite all families to join us virtually, for our June 18th Med Ad News Manny Awards #FamilyStyle! This year’s Manny Awards program will be designed to entertain, engage and educate our growing healthcare communications family. Set your calendars and make a night of it for the entire family to get dressed up for a virtual Black Tie event!

May 14, 2020/by Andrew Humphreys

Biopharma/Biotech Annual Report: The world versus COVID-19

Annual Reports, April 2020, Biopharma/Biotech Annual Report, Business, Coronavirus Disease (COVID-19) Pandemic, Issue Archives, Med Ad News, R&D, Special Reports, State of the Bio Industry, Therapeutics

Scientists, researchers, health officials, regulatory agencies, governments, businesses, universities, and many others across the globe are searching for ways to defeat the coronavirus pandemic.

April 27, 2020/by Andrew Humphreys

FDA Approval Review: January-April 2020

Annual Reports, Approvals, April 2020, Biologics License Application (BLA), Biopharma/Biotech Annual Report, FDA, FDA/Regulatory, Issue Archives, Med Ad News, New Drug Application (NDA), Special Reports, State of the Bio Industry, Therapeutics

While the healthcare industry looks for ways to combat COVID-19, the beat goes on for drug manufacturers to continue developing and seeking marketing approval for medicines to treat many diseases and conditions. Here is a look at some of the most notable U.S. new drug approvals from Jan. 1 through April 17, 2020.

April 27, 2020/by Andrew Humphreys

As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.

February 24, 2020/by Andrew Humphreys

Healthcare Agency Roundtable 2019

Annual Reports, December 2019, Healthcare Agency Roundtable, Issue Archives, Marketing & Advertising, Med Ad News, Special Reports

Executive management from the 2019 Manny Award agency and network winners & finalists provide expert insight on healthcare industry topics and predictions.

December 17, 2019/by Andrew Humphreys

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

August 11, 2019/by Andrew Humphreys

Annual Report 2019: State of the Bio Industry

Biologics, Biomarkers, Biopharmaceutical, Biosimilars, Biosimulation, Biotechnology, Issue Archives, June 2019, Special Reports, State of the Bio Industry

This annual compilation reviews new developments, trends and outlooks in areas such as biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biosimulation.

June 6, 2019/by Andrew Humphreys

PulseCX: 2019

April 2019, Healthcare Communications Agencies, Healthcare Communications Agencies, Issue Archives

PulseCX is a full-service, independent, mid-sized healthcare marketing agency located just outside Philadelphia. PulseCX specializes in optimizing the customer experience (CX) for pharmaceutical brands, medical devices, and OTC products.

May 23, 2019/by Administrator

2019 Annual Report: Healthcare Communications Agencies Overview – Another Year Of Changes, Growth

April 2019, DTC, Healthcare Communications Agencies, Healthcare Communications Agencies, Issue Archives, Marketing & Advertising, Med Ad News, Special Reports

The healthcare ad industry continues to thrive and adapt to the new demands for relevance and creativity.

April 20, 2019/by Christiane Truelove

Top 10 Pipelines To Watch: 2019 Annual Report

Analysts, Ankylosing Spondylitis (AS), Annual Reports, Antiretroviral Drugs, Atopic Dermatitis (Eczema), Autoimmune Diseases, B Cells, BRCA Gene, BRCA mutation, Big Pharma, Biologics, Biopharma, Biotechnology, Blockbusters, Breakthrough Therapy Designation, Business, CAR-T Therapy, Cancer, Cells, Chemotherapy, Clinical Data, Clinical Trials, Collaborations, Crohn's Disease, Cystic Fibrosis, Drug Discovery, EU, European Medicines Agency (EMA), FDA, FDA/Regulatory, Fast Track Designation, February 2019, Future Blockbusters, Gene Editing, Generalized Myasthenia Gravis (gMG), Genomics, HIV, Human Genome, Immune Cells, Immune System, Immune-Mediated Diseases, Immunotherapy, Inflammatory Diseases, Injectables, Innovation, Integrase strand transfer inhibitors, Issue Archives, Japan, M&A, Med Ad News, Monoclonal Antibodies, Multiple myeloma, Neoantigens, Neurology, Neuromyelitis Optica Spectrum Disorder (NMOSD), New Drug Applications, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Non-Small Cell Lung Cancer (NSCLC), Nonalcoholic Steatohepatitis (NASH), Nuclear Medicine, Oncology, Orphan Drug Designation, Paroxysmal Nocturnal Hemoglobinuria (PNH), Precision Medicine, Prescription Drug User Fee Act (PDUFA), Priority Medicines (PRIME) Designation, Priority Review Voucher, Product Pipelines, Proteins, Psoriatic Arthritis, R&D, RNA Interference (RNAi), Radioligands, Rare Disorders, Research, Rheumatoid Arthritis, Sickle Cell Disease, Small Molecules, Special Reports, T-Cells, Top 10 Pipelines, Top 10 Pipelines To Watch, Tumors, Ulcerative Colitis, Ultra Rare Diseases

The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.

February 13, 2019/by Andrew Humphreys